S.Korea says Moderna reports 'production issue' as vaccination widens to 50s



(Updates with Moderna production issue)

By Sangmi Cha and Hyonhee Shin

SEOUL, July 26 (Reuters) - South Korea said on Monday it has been informed by Moderna MRNA.O of an unspecified production issue involving its COVID-19 vaccine, as the country expands its inoculation campaign for people aged 55-59 amid a fourth wave of infections.

It was not immediately clear what the production issue is, how much and long shipment will be impacted and whether other countries will be also affected by the problem.

Moderna did not immediately reply to a Reuters' request for comment.

"Moderna has informed that it has a production issue," health official Park Jin-young told a briefing, adding that consultations are being held to figure out details.

"We're mobilising all available administrative and diplomatic capabilities to establish facts and devise countermeasures," Park said.

South Korea has been struggling to turbocharge its immunisation drive amid supply shortages and shipment delays, with about 33% of its 52 million population having received at least one dose and 13% fully vaccinated.

About 6.17 million people, or 84% of those in their 50s, have signed up for this week's vaccinations, and authorities had already switched to Pfizer PFE.N /BioNTech's 22UAy.DE products from Moderna for some people in the group because of shipment delays.

But the production issue would not affect the total shipment volume planned for this month, Korea Disease Control and Prevention Agency (KDCA) director Jeong Eun-kyeong said, without providing specific numbers.

South Korea has a contract for 40 million doses of the Moderna vaccine, of which about 1.1 million have arrived so far.

The vaccine rollout for people in their upper 50s had sputtered to a week-long halt this month after a record high number of new cases sparked a rush for shots, exhausting available supplies and crashing an official reservation website. .

Mass testing and tracing have helped the country suffer lower COVID-19 death rates than other developed countries so far without a full lockdown, but the new wave of infections prompted the government on Sunday to tighten social distancing rules across most of the country this week to head off transmission in the summer holidays.

The KDCA reported 1,318 new coronavirus cases for Sunday, bringing total infections to 190,166, with 2,077 deaths.
Reporting by Sangmi Cha and Hyonhee Shin; Editing by Gerry Doyle and Louise Heavens

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.